Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study
This study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.
Authors
- Tomoya Yokota (ORCID: https://orcid.org/0000-0001-7327-7949)
- Yasuyoshi Sato (ORCID: https://orcid.org/0000-0003-4145-8694)
- Hiroaki Iijima (ORCID: https://orcid.org/0000-0002-3343-9111)
- Satoshi Kano (ORCID: https://orcid.org/0000-0003-4750-5332)
- Shunji Takahashi (ORCID: https://orcid.org/0000-0002-5031-1953)
- Yoshihiko Kumai
- Kengo Nagashima (ORCID: https://orcid.org/0000-0003-4529-9045)
- Naomi Kiyota (ORCID: https://orcid.org/0000-0001-8021-6116)
- Nobuhiko Oridate (ORCID: https://orcid.org/0000-0002-6968-3028)
- Kazue Ito (ORCID: https://orcid.org/0000-0002-0335-2170)
- Yasushi Shimizu (ORCID: https://orcid.org/0000-0003-2624-4305)
- Taiji Koyama (ORCID: https://orcid.org/0000-0002-2893-605X)
- Kenji Okami (ORCID: https://orcid.org/0000-0003-4228-3347)
- Shigenori Kadowaki (ORCID: https://orcid.org/0000-0001-9923-5309)
- Hideaki E. Takahashi (ORCID: https://orcid.org/0000-0001-6197-5432)
- Yoshitaka Honma (ORCID: https://orcid.org/0000-0002-4209-4493)
- Hideaki Nishi
- Tomoko Yamazaki
- Kyoko Kato
- Takane Watanabe (ORCID: https://orcid.org/0009-0008-3817-9874)
- Hiroki Oka
Institutions
- Shizuoka Cancer Center (JP)
- National Cancer Center (US)
- Kobe University Hospital (JP)
- Yokohama City University Hospital (JP)
- Keio University Hospital (JP)
- Miyagi Prefectural Hospital Organization (JP)
- Tokai University Hospital (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Hokkaido University Hospital (JP)
- Nagasaki University Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1093/oncolo/oyaf018
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Taiho Pharmaceutical
- Nihon Medi-Physics
- Kowa Company
- Incyte
- Rakuten Medical
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Shionogi
- Otsuka Pharmaceutical
- Toray Industries
- Teijin Pharma
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe